Mindset Pharma Inc. announced that it has engaged a leading international contract development and manufacturing organization to synthesize a 1.0 kg batch of cGMP psilocybin utilizing Mindset's innovative and cost-effective patent- pending synthesis process. The large scale cGMP synthesis batch is expected to be released in the fall of 2021. Mindset anticipates that there will be significant demand for its proprietary, high-quality psilocybin supply given the increasing number of trials and studies underway utilizing psilocybin. High-quality psilocybin for clinical research purposes is currently expensive and difficult to procure, however Mindset's cost-effective patent-pending synthesis process provides Mindset with a unique advantage to accelerate the commercialization of its portfolio of intellectual property. Several CDMOs that specialize in psilocybin synthesis have exclusive relationships with individual clients, further narrowing the range of psilocybin supply options. Additionally, Mindset is not aware of any existing psilocybin suppliers that have synthesized a commercial quantity at a scale exceeding 1.0kg.